Yang Minglei, Ma Xiaoyu, Wang Pengru, Yang Jiaxiang, Zhong Nanzhe, Liu Yujie, Shen Jun, Wan Wei, Jiao Jian, Xu Wei, Xiao Jianru
Department of Orthopedic Oncology, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Department of Orthopedics, Traditional Chinese Hospital of LuAn, Anhui, China.
Global Spine J. 2024 Jan;14(1):283-294. doi: 10.1177/21925682221103833. Epub 2022 May 26.
Retrospective and prospective cohort study.
Survival estimation is necessary in the decision-making process for treatment in patients with spinal metastasis from cancer of unknown primary (SMCUP). We aimed to develop a novel survival prediction system and compare its accuracy with that of existing survival models.
A retrospective derivation cohort of 268 patients and a prospective validation cohort of 105 patients with SMCUP were performed. Univariate and multivariable survival analysis were used to generate independently prognostic variables. A nomogram model for survival prediction was established by integrating these independent predictors based on the size of the significant variables' regression coefficient. Then, the model was subjected to bootstrap validation with calibration curves and concordance index (C-index). Finally, predictive accuracy was compared with Tomita, revised Tokuhashi and SORG score by the receiver-operating characteristic (ROC) curve.
The survival prediction model included six independent prognostic factors, including pathology ( < .001), visceral metastases ( < .001), Frankel score ( < .001), weight loss ( = .005), hemoglobin ( = .001) and serum tumor markers ( < .001). Calibration curve of the model showed good agreement between predicted and actual mortality risk in 6-, 12-, and 24-month estimation in derivation and validation cohorts. The C-index was .775 in the derivation cohort and .771 in the validation cohort. ROC curve analysis showed that the current model had the best accuracy for SMCUP survival estimation amongst 4 models.
The novel nomogram system can be applied in survival prediction for SMCUP patients, and furtherly be used to give individualized therapeutic suggestions based on patients' prognosis.
回顾性和前瞻性队列研究。
在未知原发癌的脊柱转移瘤(SMCUP)患者的治疗决策过程中,生存估计是必要的。我们旨在开发一种新的生存预测系统,并将其准确性与现有的生存模型进行比较。
对268例患者进行回顾性推导队列研究,对105例SMCUP患者进行前瞻性验证队列研究。采用单因素和多因素生存分析来生成独立的预后变量。基于显著变量回归系数的大小,通过整合这些独立预测因子建立生存预测列线图模型。然后,使用校准曲线和一致性指数(C指数)对该模型进行自举验证。最后,通过受试者操作特征(ROC)曲线将预测准确性与富田、修订后的德桥和SORG评分进行比较。
生存预测模型包括六个独立的预后因素,包括病理(<.001)、内脏转移(<.001)、弗兰克尔评分(<.001)、体重减轻(=.005)、血红蛋白(=.001)和血清肿瘤标志物(<.001)。该模型的校准曲线显示,在推导队列和验证队列的6个月、12个月和24个月估计中,预测的和实际的死亡风险之间具有良好的一致性。推导队列中的C指数为.775,验证队列中的C指数为.771。ROC曲线分析表明,在4种模型中,当前模型对SMCUP生存估计的准确性最高。
新型列线图系统可应用于SMCUP患者的生存预测,并进一步用于根据患者预后提供个体化治疗建议。